Serap Erkek

Dr. Serap Erkek


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2018 in Nature
Verified
Journal Article
Open access
PDF file
IPICGC PedBrain-Seq Project
ICGC PedBrain-Seq Project
SGSusanne N. Gröbner
Susanne N. Gröbner
IPIcgc Mmml-Seq Project
Icgc Mmml-Seq Project
BWBarbara C. Worst
Barbara C. Worst
JWJoachim Weischenfeldt
Joachim Weischenfeldt
Stefan PfisterStefan Pfister
Stefan Pfister
Pan-cancer analyses that examine commonalities and differences among various cancer types have emerged as a powerful way to obtain novel insights into cancer biology. Here we present a comprehensive analysis of genetic alterations in a pan-cancer cohort including 961 tumours from children, adolescents, and young adults, comprising 24 distinct molecular types of cancer. Using a standardized workflow, we identified marked differences in terms of mutation frequency and significantly mutated genes in comparison to previously analysed adult cancers. Genetic alterations in 149 putative cancer driver genes separate the tumours into two classes: small mutation and structural/copy-number variant (correlating with germline variants). Structural variants, hyperdiploidy, and chromothripsis are linked to TP53 mutation status and mutational signatures. Our data suggest that 7–8% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.

20 July 2017 in Nature
Verified
Journal Article
Open access
PDF file
PNPaul A. Northcott
Paul A. Northcott
IBIvo Buchhalter
Ivo Buchhalter
AMA. Sorana Morrissy
A. Sorana Morrissy
VHVolker Hovestadt
Volker Hovestadt
JWJoachim Weischenfeldt
Joachim Weischenfeldt
PLPeter Lichter
Peter Lichter
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma.

16 May 2010 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
UBUrszula Brykczynska
Urszula Brykczynska
MHMizue Hisano
Mizue Hisano
SESerap Erkek
Serap Erkek
LRLiliana Ramos
Liliana Ramos
EOEdward J Oakeley
Edward J Oakeley
APAntoine H F M Peters
Antoine H F M Peters

22 June 2014 in Nature
Verified
Journal Article
Open access
PDF file
PNPaul A. Northcott
Paul A. Northcott
CLCatherine Lee
Catherine Lee
TZThomas Zichner
Thomas Zichner
ASAdrian M. Stütz
Adrian M. Stütz
SESerap Erkek
Serap Erkek
Stefan PfisterStefan Pfister
Stefan Pfister
Medulloblastoma is a highly malignant paediatric brain tumour currently treated with a combination of surgery, radiation and chemotherapy, posing a considerable burden of toxicity to the developing child. Genomics has illuminated the extensive intertumoral heterogeneity of medulloblastoma, identifying four distinct molecular subgroups. Group 3 and group 4 subgroup medulloblastomas account for most paediatric cases; yet, oncogenic drivers for these subtypes remain largely unidentified. Here we describe a series of prevalent, highly disparate genomic structural variants, restricted to groups 3 and 4, resulting in specific and mutually exclusive activation of the growth factor independent 1 family proto-oncogenes, GFI1 and GFI1B. Somatic structural variants juxtapose GFI1 or GFI1B coding sequences proximal to active enhancer elements, including super-enhancers, instigating oncogenic activity. Our results, supported by evidence from mouse models, identify GFI1 and GFI1B as prominent medulloblastoma oncogenes and implicate ‘enhancer hijacking’ as an efficient mechanism driving oncogene activation in a childhood cancer.

15 August 2014 in Science
Verified
Journal Article
Closed access
ERElizabeth Radford
Elizabeth Radford
MIMitsuteru Ito
Mitsuteru Ito
HSHui Shi
Hui Shi
JCJennifer A. Corish
Jennifer A. Corish
KYKazuki Yamazawa
Kazuki Yamazawa
AFAnne C. Ferguson-Smith
Anne C. Ferguson-Smith
The nutritional sins of the mother…: Prenatal exposures of a mother can affect the health of her offspring, but how? Radford et al. found that the male progeny of undernourished pregnant mice had altered DNA chemistry in their sperm. In addition, the offspring displayed compromised metabolic health. The specific affected genes not only lost DNA methylation but also lacked the normal sperm DNA packaging factors (protamines) and instead were enriched in nucleosomes. Thus, when subjected to a suboptimal prenatal environment, offspring feel the effects of the maternal assault. Science , this issue p. 10.1126/science.1255903

1 March 2016 in Cancer Cell
Verified
Journal Article
Closed access
PJPascal D. Johann
Pascal D. Johann
SESerap Erkek
Serap Erkek
MZMarc Zapatka
Marc Zapatka
KKKornelius Kerl
Kornelius Kerl
IBIvo Buchhalter
Ivo Buchhalter
MKMarcel Kool
Marcel Kool